Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protective effect of notoginsenoside R1 on small intestine ischemia/reperfusion injury

A technology of ischemia-reperfusion and notoginseng saponins, applied to medical preparations containing active ingredients, digestive system, organic active ingredients, etc., can solve the problem of no report on the protective effect of small intestine ischemia-reperfusion injury in vivo

Inactive Publication Date: 2014-12-17
TIANJIN TASLY PHARMA CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the protective effect of R1 on small intestinal ischemia-reperfusion injury in vivo has not yet been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protective effect of notoginsenoside R1 on small intestine ischemia/reperfusion injury
  • Protective effect of notoginsenoside R1 on small intestine ischemia/reperfusion injury
  • Protective effect of notoginsenoside R1 on small intestine ischemia/reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0146] tablet

[0147] 【prescription】

[0148] Notoginsenoside R1 100g

[0149] Microcrystalline cellulose 50g

[0150] Micronized silica gel 3g

[0151] Magnesium stearate 1.5g

[0152] [Preparation method] Take the original and auxiliary materials through a 100-mesh sieve; take the notoginsenoside R1 and microcrystalline cellulose, mix them, use 60% ethanol as a binder to make a soft material, and pass through a 20-mesh sieve to make granules, 60℃ Dry, take out, sieved through a 30-mesh sieve, add micro-powdered silica gel and magnesium stearate, mix well, and press to make 1000 tablets, which are ready to be obtained.

Embodiment 2

[0154] 【prescription】

[0155] Notoginsenoside R1 75g

[0156] Microcrystalline cellulose 37g

[0157] Micronized silica gel 2.3g

[0158] Magnesium stearate 1.1g

[0159] [Preparation method] Take the original and auxiliary materials through a 100-mesh sieve; take the notoginsenoside R1 and microcrystalline cellulose, mix them, use 60% ethanol as a binder to make a soft material, and pass through a 20-mesh sieve to make granules, 60℃ Dry, take out, sieving through a 30-mesh sieve, add appropriate amount of finely powdered silica gel and magnesium stearate, mix well, and press to make 1000 tablets, ready to be obtained.

Embodiment 3

[0161] 【prescription】

[0162] Notoginsenoside R1 133g

[0163] Microcrystalline cellulose 66g

[0164] Micronized silica gel 4g

[0165] Magnesium stearate 2g

[0166] [Preparation method] Take the original and auxiliary materials through a 100-mesh sieve; take the notoginsenoside R1 and microcrystalline cellulose, mix them, use 60% ethanol as a binder to make a soft material, and pass through a 20-mesh sieve to make granules, 60℃ Dry, take out, sieving through a 30-mesh sieve, add appropriate amount of finely powdered silica gel and magnesium stearate, mix well, and press to make 1000 tablets, ready to be obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of notoginsenoside R1 in preparation of drugs for treating small intestinal mucosal injury, intestinal inflammatory cell infiltration and increase in microvessel permeability caused by ischemia / reperfusion. The application is realized by a way that the notoginsenoside R1 inhibits I[kappa]B[alpha] degradation and metastasis of NF-[kappa]BP65 translocates to cell nuclei, and then inhibits inflammatory cytokine release; the application is realized by a way that the notoginsenoside R1 inhibits leukocytes to swim out of microvessels, so as to avoid infiltration in tissues; the application is realized by a way that the notoginsenoside R1 inhibits cell apoptosis; the application is realized by a way that the notoginsenoside R1 inhibits degradation of vascular intercellular tight-junction proteins and inhibits plasma albumin leakage; and the application is realized by a way that the notoginsenoside R1 regulates ATP5D, increases the content of ATP in intestinal canal tissues, and promotes repair of intestinal mucosa epithelial cells.

Description

Technical field [0001] The invention relates to the application of a medicine, in particular to the protective effect of notoginsenoside R1 on small intestinal ischemia-reperfusion injury. Background technique [0002] Small bowel ischemia / reperfusion (I / R) injury can occur under many conditions, such as superior mesenteric artery embolism, small bowel transplantation, cardiopulmonary bypass, abdominal aortic aneurysm surgery, trauma or hemorrhagic shock. Small bowel ischemia-reperfusion can lead to sepsis, systemic inflammatory response syndrome and multiple organ failure, with high incidence and mortality. [0003] The generation of oxygen free radicals and the initiation of the inflammatory cascade have long been considered to be the two main mechanisms that cause small bowel ischemia-reperfusion injury. Treatment targeting oxidative stress and inflammation has always been the focus of previous research. However, the results are still unsatisfactory. Because the oxidative str...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P1/00A61P29/00
Inventor 韩晶岩李翀李泉刘育英王明暇潘春水阎丽陈媛媛
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com